Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

10.17
+0.30003.04%
Pre-market: 10.210.0400+0.39%07:10 EDT
Volume:2.08M
Turnover:21.39M
Market Cap:867.64M
PE:-5.83
High:10.75
Open:9.84
Low:9.68
Close:9.87
52wk High:25.77
52wk Low:7.44
Shares:85.31M
Float Shares:54.48M
Volume Ratio:1.18
T/O Rate:3.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7450
EPS(LYR):-0.4650
ROE:-42.66%
ROA:-21.63%
PB:1.78
PE(LYR):-21.87

Loading ...

Monte Rosa Publishes Corporate Presentation on Targeted Protein Degradation Pipeline and Molecular Glue Degraders

Reuters
·
Aug 06

Monte Rosa Activates Phase 2 MODeFIRe-1 Trial of MRT-2359 Plus Apalutamide in Metastatic Prostate Cancer

Reuters
·
Aug 06

Monte Rosa Q2 FY26 Net Loss Widens to $43.4 Million; Revenue Falls 61.3% to $9 Million

Reuters
·
Aug 06

Monte Rosa Therapeutics Q2 Operating Expenses USD 58.098 Million

THOMSON REUTERS
·
Aug 06

Monte Rosa’s MODeFIRe-1 Trial Pushes GLUE Into a Key Mid-Stage Prostate Cancer Test

TIPRANKS
·
Aug 05

Monte Rosa Therapeutics is Maintained at Outperform by Wedbush

Dow Jones
·
Aug 03

Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback

TIPRANKS
·
Aug 01

Monte Rosa Therapeutics price target lowered at Jefferies after Novo trial miss

TIPRANKS
·
Aug 01

Monte Rosa Tumbles on Read-through from Novo's Cardiovascular Trial Failure

Reuters
·
Jul 31

Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating

MT Newswires Live
·
Jul 31

Have Insiders Sold Monte Rosa Therapeutics Shares Recently?

Simply Wall St.
·
Jul 20

Monte Rosa CEO Markus Warmuth Sells 9,500 Shares Worth $220,219.55

Reuters
·
Jul 18

Monte Rosa COO Jennifer Champoux Disposes of 4,351 Common Shares Worth $101,707.28

Reuters
·
Jul 17

Analysts Are Bullish on These Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Neurocrine (NBIX)

TIPRANKS
·
Jul 13

Monte Rosa CSO Sharon Townson Disposes of Common Shares Worth $140,297.2

Reuters
·
Jul 08

Monte Rosa Therapeutics Grants Inducement Awards to New Hires, Including Options for 18,025 Shares at $24.02

Reuters
·
Jul 03

Monte Rosa Therapeutics CMO Filip Janku Disposes of 5,407 Common Shares Worth $132,471.50

Reuters
·
Jul 02

Monte Rosa Therapeutics Director Anthony M. Manning Disposes of 10,000 Common Shares Worth $231,100

Reuters
·
Jul 01

Monte Rosa Therapeutics is Maintained at Buy by Guggenheim

Dow Jones
·
Jun 30

Guggenheim Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Jun 30